Time to pediatric epilepsy surgery is longer and developmental outcomes lower for government compared with private

Jason S Hauptman1, Andrew Dadour, Taemin Oh

  • 1Department of Neurosurgery, Mattel Children's Hospital, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

Neurosurgery
|April 26, 2013
PubMed

Insights

Children with private insurance experienced shorter wait times for epilepsy surgery compared to those with Medicaid. This difference in access was linked to lower developmental scores in children with Medicaid before surgery, suggesting potential delays in care.

Area of Science:

  • Pediatric Neurology
  • Health Services Research
  • Socioeconomic Determinants of Health

Background:

  • Socioeconomic factors, including insurance type, may impact the timing of epilepsy surgery referral and subsequent developmental outcomes in pediatric patients.
  • Understanding these disparities is crucial for improving access to timely surgical intervention for children with epilepsy.

Purpose of the Study:

  • To investigate the association between insurance type (private vs. state-provided Medicaid) and the time interval from seizure onset to epilepsy surgery in pediatric patients.
  • To determine if insurance type influences developmental quotients (DQ) in pediatric patients undergoing epilepsy surgery.

Main Methods:

  • Retrospective cohort study of 420 pediatric patients undergoing epilepsy surgery.
  • Patients were categorized by insurance: Medicaid (California Children's Services) or private insurance (PPO, HMO, Indemnity).
  • Time intervals (seizure onset to referral, seizure onset to surgery) and Vineland developmental assessments were compared between insurance groups using log-rank tests.

Main Results:

  • Children with Medicaid had significantly longer intervals from seizure onset to referral and to surgery compared to those with private insurance.
  • A subset of children with Medicaid showed lower pre- and post-surgery Vineland scores compared to those with private insurance.
  • Insurance type did not correlate with seizure severity, surgical approach, etiology, seizure control post-surgery, or complication rates.

Conclusions:

  • Private insurance is associated with shorter referral and surgical intervals for pediatric epilepsy surgery compared to Medicaid.
  • Shorter intervals in the private insurance group may be linked to better developmental outcomes, although lower scores were observed in the Medicaid group pre-surgery.
  • Findings suggest potential delays in access to care for children with state insurance, necessitating further investigation into long-term developmental impacts.
Abstract

Related Concept Videos

Psychosurgery01:30

Psychosurgery

Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...